NCT00316589

Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts >200 - 750/µl.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 581 (actual)
• Sponsor: Bavarian Nordic · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations. Subjects will receive two vaccinations

Conditions

• HIV Infections

Interventions

Type	Name	Description
BIOLOGICAL	IMVAMUNE (MVA-BN)	2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous

Timeline

• Start date: 2006-06-01
• Primary completion: 2009-03-01
• Completion: 2009-10-01
• First posted: 2006-04-21
• Last updated: 2019-01-03
• Results posted: 2019-01-03

Locations

36 sites across 2 countries: United States, Puerto Rico